By clicking “Accept All Cookies” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Privacy PolicyClosed System Bioprocessing Market (By Product: Bioreactors, Fermenters, Mixing Systems, Filtration Systems, and Others; By Application: Biopharmaceutical Production, Vaccine Manufacturing, Cell and Gene Therapy, Regenerative Medicine, and Others; By End Use: Pharmaceutical & Biotech Companies, Contract Manufacturing Organizations, and Research & Academic Institutes; By Region: North America, LAMEA, Europe, Asia-Pacific) Industry Size, Share, Growth, Trends 2026 to 2035.
The global closed system bioprocessing market is projected to grow from USD 10.97 billion in 2025 to USD 25.97 billion by 2035, at a compound annual growth rate (CAGR) of 9%. This growth is driven by increased demand for efficient, scalable biomanufacturing solutions in the pharmaceutical and biotechnology sectors.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 10.97 Billion |
| Market Size in 2026 | USD 11.96 Billion |
| Market Size in 2032 | USD 20.05 Billion |
| Market Size by 2035 | USD 25.97 Billion |
| CAGR 2026 to 2035 | 9% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The closed system bioprocessing is one of the manufacturing ideas that segregates the processed materials and the products from the area that could impact the quality of the product, ensuring a safe environment without any disturbance to the ecosystem and product. The comprehensive technologies encompass the market’s active involvement in the healthcare sector, mainly.
The technologies, such as in-line sensors, aseptic connectors, and single-use technology, promote various uses and roles of the closed system bioprocessing. The two types of closed system bioprocessing are functionally closed system and fully closed system, which demonstrates the clear potential of the closed system bioprocessing market. The closed system bioprocessing enables affordable production without any need for cleanrooms. It’s safe, and its energy-saving capability brings more value and business to the market as a whole.
| Regions | Shares (%) |
| North America | 35% |
| Europe | 30% |
| Asia Pacific | 25% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Bioreactors | 35% |
| Fermenters | 30% |
| Mixing Systems | 20% |
| Filtration Systems | 10% |
| Others | 5% |
| Segments | Shares (%) |
| Biopharmaceutical Production | 40% |
| Vaccine Manufacturing | 25% |
| Cell And Gene Therapy | 20% |
| Regenerative Medicine | 10% |
| Others | 5% |
| Segments | Shares (%) |
| Commercial Buildings | 35% |
| Pharmaceutical & Biotech Companies | 50% |
| Contract Manufacturing Organizations | 30% |
| Research & Academic Institutes | 20% |
Published by Ajit Bansod
| Application | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceutical Production | 4.39 | 4.78 | 5.31 | 5.69 | 6.17 | 6.74 | 7.32 | 7.92 | 8.72 | 9.44 | 10.37 |
| Vaccine Manufacturing | 2.73 | 3.00 | 3.23 | 3.54 | 3.95 | 4.22 | 4.67 | 5.08 | 5.44 | 5.97 | 6.47 |
| Cell And Gene Therapy | 2.18 | 2.36 | 2.65 | 2.81 | 3.05 | 3.40 | 3.63 | 4.02 | 4.36 | 4.71 | 5.20 |
| Regenerative Medicine | 1.11 | 1.20 | 1.25 | 1.48 | 1.55 | 1.73 | 1.82 | 2.00 | 2.22 | 2.44 | 2.50 |
| Others | 0.56 | 0.62 | 0.59 | 0.69 | 0.77 | 0.79 | 0.95 | 1.04 | 1.12 | 1.26 | 1.43 |
| End Use | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biotech Companies | 5.47 | 5.99 | 6.56 | 7.06 | 7.72 | 8.42 | 9.17 | 9.98 | 11.02 | 12.00 | 12.87 |
| Contract Manufacturing Organizations | 3.30 | 3.54 | 3.86 | 4.28 | 4.62 | 5.05 | 5.57 | 6.10 | 6.55 | 7.08 | 7.84 |
| Research & Academic Institutes | 2.20 | 2.42 | 2.61 | 2.87 | 3.14 | 3.41 | 3.66 | 3.97 | 4.28 | 4.75 | 5.27 |
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 3.82 | 4.19 | 4.53 | 5.00 | 5.41 | 5.88 | 6.38 | 6.96 | 7.72 | 8.35 | 9.09 |
| Europe | 3.29 | 3.57 | 3.99 | 4.23 | 4.60 | 5.15 | 5.54 | 6.00 | 6.44 | 7.00 | 7.74 |
| Asia Pacific | 2.76 | 2.98 | 3.26 | 3.53 | 3.97 | 4.23 | 4.63 | 5.03 | 5.47 | 6.00 | 6.61 |
| LAMEA | 1.10 | 1.22 | 1.26 | 1.45 | 1.50 | 1.63 | 1.85 | 2.06 | 2.23 | 2.48 | 2.53 |
| Subsegment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceutical Production | 4.39 | 4.78 | 5.31 | 5.69 | 6.17 | 6.74 | 7.32 | 7.92 | 8.72 | 9.44 | 10.37 |
| Vaccine Manufacturing | 2.73 | 3.00 | 3.23 | 3.54 | 3.95 | 4.22 | 4.67 | 5.08 | 5.44 | 5.97 | 6.47 |
| Cell And Gene Therapy | 2.18 | 2.36 | 2.65 | 2.81 | 3.05 | 3.40 | 3.63 | 4.02 | 4.36 | 4.71 | 5.20 |
| Regenerative Medicine | 1.11 | 1.20 | 1.25 | 1.48 | 1.55 | 1.73 | 1.82 | 2.00 | 2.22 | 2.44 | 2.50 |
| Others | 0.56 | 0.62 | 0.59 | 0.69 | 0.77 | 0.79 | 0.95 | 1.04 | 1.12 | 1.26 | 1.43 |
| Subsegment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biotech Companies | 5.47 | 5.99 | 6.56 | 7.06 | 7.72 | 8.42 | 9.17 | 9.98 | 11.02 | 12.00 | 12.87 |
| Contract Manufacturing Organizations | 3.30 | 3.54 | 3.86 | 4.28 | 4.62 | 5.05 | 5.57 | 6.10 | 6.55 | 7.08 | 7.84 |
| Research & Academic Institutes | 2.20 | 2.42 | 2.61 | 2.87 | 3.14 | 3.41 | 3.66 | 3.97 | 4.28 | 4.75 | 5.27 |
| Subsegment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 3.82 | 4.19 | 4.53 | 5.00 | 5.41 | 5.88 | 6.38 | 6.96 | 7.72 | 8.35 | 9.09 |
| Europe | 3.29 | 3.57 | 3.99 | 4.23 | 4.60 | 5.15 | 5.54 | 6.00 | 6.44 | 7.00 | 7.74 |
| Asia Pacific | 2.76 | 2.98 | 3.26 | 3.53 | 3.97 | 4.23 | 4.63 | 5.03 | 5.47 | 6.00 | 6.61 |
| LAMEA | 1.10 | 1.22 | 1.26 | 1.45 | 1.50 | 1.63 | 1.85 | 2.06 | 2.23 | 2.48 | 2.53 |
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Our customers work more efficiently and benefit from
